A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Strategic leadership appointment strengthens company’s commercial approach to drive continued growth and deliver long-term value ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine Corps veteran and the executive director of Healing Breakthrough.

SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc.

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Dusquetide (SGX945) Granted Orphan Drug Designation for the Treatment ...

Stroke often results in persistent gait impairments, limiting mobility and reducing quality of life. This study evaluated FAST walk, a novel electromyography-triggered system that combines ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...